PILOT STUDY OF INHALED NITRIC OXIDE IN PATIENTS WITH CYSTIC FIBROSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 囊性纤维症患者呼吸道内一氧化氮(NO)减少。吸入NO具有良好的抗炎和抗菌作用，有可能成为治疗慢性肺病的有效药物。这个初步项目的主要目标是评估吸入NO在2天内对患有CF的年龄较大的儿童和成人的安全性和耐受性。长期目标是确定吸入NO对慢性肺病急性加重期患者是一种有效的治疗策略，甚至是对患有严重肺部疾病的慢性肺病患者是有效的治疗策略。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nitric oxide (NO) is decreased in the airways of persons with cystic fibrosis (CF). Inhaled NO has the potential to be an effective treatment in CF lung disease, especially because of its anti-inflammatory and antimicrobial activities. The main objective of this initial project is to evaluate the safety and tolerability of inhaled NO over a 2 day period in older children and adults with CF. The long term objectives are to determine whether inhaled NO may be a useful therapeutic strategy for CF patients during an acute pulmonary exacerbation or even as a chronic therapy in CF patients with severe lung disease.